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Immune checkpoint inhibitors (ICIs) are now an important component of the standard of care in patients with non-small-cell lung cancer (NSCLC). ICIs have shown a survival advantage in pretreated patients in multiple randomized clinical trials (RCTs) 1-4 that enrolled only patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 1. In the first-line setting, ICIs were evaluated as a single agent or in combination with chemotherapy in multiple RCTs but, again, only in patients with a PS of 0 to 1. 5, 6 However, in either first-line or second-line therapy, these drugs have received approval from the US Food and Drug Administration and European Medicines Agency regardless of the PS of patients. Hence, an important question in everyday clinical practice is whether these data from RCTs can be extrapolated to the real world for patients with a PS of more than 1.
In the preimmunotherapy era, RCTs evaluating chemotherapy or targeted agents in NSCLC have been conducted stratifying patients into ECOG PS 0 to 1 versus PS 2. This stratification made clinical sense, considering that PS is the most powerful independent prognostic factor in advanced NSCLC and predictor of response and adverse events (AEs). 7 Nevertheless, patients with ECOG PS 2 represent a heterogeneous population. Per definition, PS 2 is applied to a patient who is ambulatory and capable of all self-care but is unable to perform any work activities and to be active for more than 50% of waking hours. 8 The definition does not take age, tumor burden, comorbidities, polypharmacy, and so on into account separately. Furthermore, the definition lends itself to subjective categorization, and evidence suggests that patient-reported PS differs from physician-reported PS; even two physicians may not necessarily categorize the same patient with the same PS category. 9, 10 Thus, the PS 2 category in the real world could encompass different subgroups of patients with different risk-benefit ratios and prognoses who deserve more tailored treatments. Unfortunately, however, unlike the chemotherapy trials, patients with ECOG PS 2 have been excluded from the majority of ICI trials. [11] [12] [13] [14] [15] [16] [17] [18] [19] Hence, whether to treat these patients with ICIs is an important and common clinical dilemma, considering that ECOG PS 2 patients account for 30% to 40% of all patients with NSCLC.
To date, 11 pivotal phase III RCTs have estimated the activity of different ICIs (atezolizumab, nivolumab, pembrolizumab, durvalumab, and ipilimumab) in locally advanced and advanced disease settings as both first-line and second-line treatment, but always excluding patients with ECOG PS 2. [1] [2] [3] [4] [5] [6] [20] [21] [22] [23] [24] A recent meta-analysis of 18 trials across multiple tumor types (NSCLC, small-cell lung cancer, melanoma, prostate cancer, head and neck cancer, gastric cancer, and urothelial cancer) revealed that the overall survival (OS) difference between PS 0 and PS 1 to 2 patients treated with ICIs was not significant (P 5 .99). 25 However, the number of patients with PS 2 or higher was too small (only 54 of 11,354 patients) to allow drawing any definitive conclusion for this group of patients. It will be more meaningful in future metaanalyses to group PS 0 and 1 patients together and compare them with PS 2 patients, assuming future RCTs will include more patients with PS 2. To date, the only trial in any tumor type where a comparison between patients with PS 0 to 1 versus those with PS 2 was made is the KEYNOTE-045 trial of pembrolizumab in urothelial cancer. 26 Although this trial showed a significant advantage for pembrolizumab in the overall and PS 0 or 1 population, the benefit was not significant for PS 2 patients. However, this lack of benefit is inconclusive, given that there were only six patients in this cohort.
Patients with NSCLC with PS 2 are a heterogeneous group, usually with a large tumor burden in conjunction with chronic obstructive pulmonary disease (COPD) or other smoking-related diseases, necessitating frequent treatment with corticosteroids. A study has now shown that daily use of corticosteroids ($ 10 mg of prednisone equivalent) was associated with a lower overall response rate, median progressionfree survival (PFS), and OS in patients with NSCLC Author affiliations and support information (if applicable) appear at the end of this article.
treated with ICIs, although only 16% of such patients had a PS of 2 or greater. 28 Furthermore, patients with restricted PS or with moderate to severe comorbidities (eg, COPD in patients with NSCLC) may also require more frequent use of antibiotics, which could alter the gut microbiota, with potential impact on outcomes with ICIs. 29, 30, 32, 33 A retrospective study of 249 patients, including 140 patients with NSCLC, treated with ICIs demonstrated that the use of antibiotics could adversely affect the clinical outcome. 31, 34 Microbiome can also alter the toxicities from ICI. 34, 35 Moreover, pneumonitis, which is a clinically important adverse effect of ICIs, could severely compromise the already dwindling pulmonary reserve of patients with NSCLC with PS 2 and could also make the differential diagnosis between pneumonitis and exacerbation of COPD more difficult. The incidence of pneumonitis overall is 4.1% and that of severe pneumonitis (grade 3 or higher) is approximately 1.8% with anti-programmed death-1 monotherapy. 36 Furthermore, patients who are heavy smokers are associated with tumors that have high tumor mutation burden, and high-tumor-mutation-burden tumors are associated with better clinical outcome when treated with ICIs. [37] [38] [39] Thus, a multitude of factors can potentially affect the response and adverse effects with ICIs in patients with PS 2 or greater.
Unfortunately, however, the evidence for making treatment decisions about using ICIs in this group of patients is scant. Among the only five trials of ICIs in NSCLC that allowed the inclusion of PS 2 patients, only one (PePS2 trial) 40 is specific to addressing the activity of ICIs in this population (Table 1) .
CheckMate-171 was a phase II single-arm trial of nivolumab in metastatic squamous NSCLC, in which 809 patients were enrolled, including elderly ($ 70 years of age) and ECOG PS 2 patients (n 5 98; 12.1%). The OS in the PS 2 patient population was 5.4 months versus 9.9 months in the overall study population. The safety profile for PS 2 patients did not differ from the overall study population, with 6% versus 5%, respectively, of patients discontinuing treatment because of grade 3 to 4 treatment-related AEs (TRAEs). 41 CheckMate-153 was a phase III/IV study evaluating the safety of nivolumab in previously pretreated squamous and nonsquamous metastatic NSCLC treated in the United States and Canada. A total of 1,375 patients were enrolled, of whom 123 (8.9%) had a PS of 2. Six-month and 1-year OS rates in the PS 2 subgroup were lower than those in the PS 0 to 1 subgroup (3.9 months v 10.5 months, respectively) and 1-year OS rates of 17% versus 44%, respectively. However, significant improvements in symptom burden were observed in the PS 2 patients at most time points, with improvement in the quality of life scores starting at 6 weeks. The rate of grade 3 to 4 AEs was 12% in patients with a PS of 0 to 1 compared with 10% in patients with a PS of 2. The death rate was less than 1% in the PS 0 to 1 patients and 2% in the PS 2 patients. 42 The activity and safety of nivolumab in routine clinical practice was also investigated in three different expanded access programs (EAPs) in Canada, France, and Italy, including a pretreated PS 2 population. [43] [44] [45] Although the safety profile evaluating TRAEs and TRAEs leading to discontinuation was comparable with the overall population, median survival was worse in patients with ECOG PS 2 (Canadian EAP: 5.9 v 9.1 months; Italian EAP: PS 2 was a predictive factor for both PFS and OS). 43, 45 However, all these studies just proved that PS 2 patients have a poorer prognosis than patients with PS 0 or 1, consistent with prior knowledge. The most important question of whether PS 2 is also a predictive marker of response to ICIs remained unanswered.
Recently, interesting preliminary data were presented from the PePS2 trial, investigating the role of pembrolizumab in ECOG PS 2 patients, including treatment-naïve and pretreated patients. 40 Globally, 60 patients were enrolled in the trial, of whom nine were treatment naïve and 15 had a strong programmed death-ligand 1 (PD-L1) expression ($ 50%). The results in the overall patient population showed an overall response rate of 28.3% and a median PFS and OS of 5.4 and 11.7 months, respectively. The grade 3 to 4 toxicity was 11.7%. Although the study population was heterogeneous, including patients receiving multiple lines of therapy and with different PD-L1 proportion scores (, 1%, 1% to 49%, $ 50%), the benefit was gained across all the groups analyzed, showing a median OS of 6.8 and 12.1 months in treatment-naïve and pretreated patients, respectively, and confirming above all that patients with strong PD-L1 expression (n 5 15) reached a median OS of 16.6 months, compared with 9.8 months in the PD-L1-negative group (n 5 9.8).
Although the findings from the PePS2 trial are encouraging, ideally, a more fruitful comparison may result from RCTs investigating the benefits and harms of ICIs versus standard chemotherapy for patients with PS 2 versus PS 0 to 1. Whether PS 2 is only a prognostic biomarker or both a prognostic and a predictive marker with ICIs is too important a question to leave unanswered, considering the possible detrimental (or lack of beneficial) effects suggested from these studies, as well as the severe financial toxicity from these expensive agents. [46] [47] [48] Because of the increasing enthusiasm toward using immunotherapies in oncology, it is easy to imagine that in the real world, patients with PS 2 or even higher receive immunotherapy fueled by the notion that these drugs are more tolerable than chemotherapies. This notion that no patient with cancer should die without getting a dose of immunotherapy, coupled with the fact that an immunotherapy discovery received last year's Nobel prize in medicine, is sure to increase the demand from both patients and physicians for the last shot at immunotherapy, something that has been labeled as desperation oncology by the lay media. 49 Because ICIs are one of the most expensive cancer drugs, this approach of desperation oncology may also lead to severe financial harms to patients, families, and society. 50 At the heart of this debate is our prime concern that we are harming PS 2 patients by offering them ICIs without any evidence from trials. This concern is justified for two reasons. First, the available data suggest that these patients may be subject to different responses from ICIs, and survival data are inferior compared with PS 0 or 1 patients. Second, an example from the use of sorafenib in hepatocellular carcinoma shows us that when a drug is used in real-world patients who do not meet the trial criteria, the results are usually much poorer compared with what is seen in RCTs. 51 Similar to the use of sorafenib in patients with liver function poorer than Child-Pugh class A, now ICIs are being used in patients with PS worse than 1; thus, the risk of these patients actually being harmed is not negligible. Although we can reasonably argue that PS 2 patients may be harmed more by chemotherapies than ICIs because of toxicities, the overarching fear is that poor PS patients who would not benefit from any treatment and who would not have been offered chemotherapy would now be offered an ICI.
The future of NSCLC treatment is moving in the direction of combination regimens of immunotherapies with chemotherapies. The combination therapies seem to produce better responses; however, survival against sequential treatment has not been compared. Patients with PS 2 are unique in that they need effective therapies to alter their poor prognoses and at the same time are not able to tolerate most therapies, even more so for combination regimens. Lacking prospective trial data and especially in the absence of comparisons against sequential therapy, it may not be appropriate to subject PS 2 patients to combination regimens.
Currently, several phase II clinical trials evaluating different ICIs (durvalumab; pembrolizumab; nivolumab plus ipilimumab) are ongoing in PS 2 patients with NSCLC, and only one (the eNERGY trial; ClinicalTrils.gov identifier: NCT03351361) is a randomized phase III trial comparing the combination of nivolumab plus ipilimumab versus a first-line carboplatin-based chemotherapy in elderly or PS 2 patients. Recently, ASCO and the Food and Drug Administration have taken praiseworthy steps to encourage the participation of elderly patients in RCTs to match the real-world use of the drugs more closely. 51 We believe that for immunotherapies, similar steps must be taken to encourage the enrollment of patients with PS 2. Indeed, until such evidence is available, this would be an area where we could use the help of real-world evidence to provide us with important signals. 52, 53 As for the individual patient in the clinic, the judgment should be made on a case-by-case basis as a shared decision between the physician and the patient until robust data are available.
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